ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results

Journal of Clinical Oncology

Volumn 22, Issue 14, 2004, Pages 2835-2841

  Bonadonna, Gianni ^a   Bonfante, Valeria ^b   Viviani, Simonetta ^b   Di Russo, Anna ^b   Villani, Fabrizio ^b   Valagussa, Pinuccia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ABVD PROTOCOL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; HODGKIN DISEASE; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADOLESCENT; ADULT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 4344699405     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.170     Document Type: Article

References (26)

1. Vlachaki MT, Ha CS, Hagemeister FB, et al: Long-term outcome of treatment for Ann Arbor stage I Hodgkin's disease: Patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys 39:609-616, 1997
2. Sears JD, Greven KM, Ferree CR, et al: Definitive irradiation in the treatment of Hodgkin's disease: Analysis of outcome, prognostic factors, and long-term complications. Cancer 79:145-151, 1997
3. Dühmke E, Franklin J, Pfreundschuh M, et al: Low-dose radiation is sufficient for the non-involved extended-field treatment in favorable early stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905-2914, 2001
4. Mauch P, Tarbell N, Weinstein H, et al: Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576-1583, 1988
5. Tubiana M, Henry-Amar M, Carde P, et al: Towards comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease: The EORTC Lymphoma Group controlled clinical trials-1964-1987. Blood 73:47-56, 1989
6. Wirth A, Chao M, Corry J, et al: Mantle irradiation alone for clinical stage I-II Hodgkin's disease: Long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 17:230-240, 1999
7. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258-2272, 1993
8. Cosset JM, Fermé C, Noordijk EM, et al: Combined modality treatment for poor prognosis stages I and II Hodgkin's disease. Semin Radiat Oncol 6:185-195, 1996
9. Specht L, Gray RG, Clarke MJ, et al: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3888 patients. J Clin Oncol 16:830-843, 1998
10. Zanini M, Viviani S, Santoro A, et al: Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage). Int J Radiat Oncol Biol Phys 30:813-819, 1994
11. Bonfante V. Santoro A, Viviani S, et al: Early stage Hodgkin's disease: Ten-year results of a nonrandomized study with radiotherapy alone or combined with MOPP. Eur J Cancer 29A:24-29, 1992
12. Carde P, Burgers JM, Henry-Amar M, et al: Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors. J Clin Oncol 6:239-252, 1988
13. Bonadonna G, Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 9:21-35, 1982
14. Duggan DB, Petroni GR, Johnson L, et al: Randomized comparison of ABVD and MOPP/ ABV hybrid for the treatment of advanced Hodgkin's Disease: Report of an Intergroup Trial. J Clin Oncol 21:607-614, 2003
15. Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837, 1986
16. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601-605, 1985
17. Lister AT, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
18. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Kaplan H: Hodgkin's Disease. Cambridge, MA, Harvard University Press, 1980
20. Connors JM, Noordijk EM, Horning SJ: Hodgkin's lymphoma: Basing the treatment on the evidence. Hematology (Am Soc Hematol Educ Program) 178-193, 2001
21. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994
22. Valagussa P, Santoro A, Bonadonna G: Thyroid, pulmonary and cardiac sequelae after treatment for Hodgkin's disease. Ann Oncol 3:111-115, 1992 (suppl 4)
23. Schilsky RL, Lewis BJ, Sherins RJ, et al: Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 93:109-114, 1980
24. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
25. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's Lymphoma: Results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003
26. Meyer R, Gospodarowicz M, Connors J, et al: A randomized phase II comparison of single-modality ABVD with a strategy that includes radiation therapy in patients with early-stage Hodgkin's disease: The HD-6 trial of the National Cancer Institute of Canada Clinical Trials Group (Eastern Cooperative Oncology Group Trial JHD06). Blood 102:26a, 2003 (abstr 81)